经阴道彩色多普勒超声用于鉴别卵巢囊肿良恶性的价值

doi:10.13491/j.issn.1004-714X.2022.06.016

中国辐射卫生

2022, Vol. 31

Issue (6): 731-734 DOI: 10.13491/j.issn.1004-714X.2022.06.016

论著

本期目录 | 过刊浏览 | 高级检索

经阴道彩色多普勒超声用于鉴别卵巢囊肿良恶性的价值

陈丽, 张小娟, 黄丽芬

江苏省常州市妇幼保健院超声科，江苏常州 213004

Clinical significance of transvaginal color Doppler ultrasound for the differential diagnosis of benign and malignant ovarian cysts

CHEN Li, ZHANG Xiaojuan, HUANG Lifen

Department of Ultrasound, Changzhou Municipal Maternal and Child Healthcare Hospital, Changzhou 213004 China

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (453 KB) HTML ( )
输出: BibTeX | EndNote (RIS)

摘要目的评价经阴道彩色多普勒超声用于诊断卵巢囊肿良恶性的价值。方法以2018—2021年接受诊疗的临床疑似或可触及的子宫附件肿块患者，且接受灰阶超声图像、经阴道彩色多普勒超声及超声引导下细针穿刺细胞学检查（FNAC）为研究对象。计算搏动指数（PI）和阻力指数（RI），以PI最低值 < 1.0或RI最低值 < 0.4定义该卵巢囊肿为恶性。以FNAC检测结果为金标准，评价灰阶超声图像和经阴道彩色多普勒超声用于鉴别卵巢囊肿良恶性的敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）。结果 180例卵巢囊肿患者中，经FNAC确诊卵巢恶性病变81例、卵巢良性病变99例。经阴道彩色多普勒超声图像上，75例卵巢恶性病变患者卵巢囊肿出现血流信号（92.59%）、42例卵巢良性病变患者卵巢囊肿出现血流信号（42.24%），差异有统计学意义（χ² = 49.29，P < 0.01）。囊肿内出现血流信号的75例卵巢恶性病变患者中，75例患者PI值均 < 1.0，24例患者RI值< 0.4；囊肿内出现血流信号的42例卵巢良性病变患者中，15例患者PI值 < 1.0，未见RI值 < 0.4的患者；囊肿内出现血流信号的卵巢良、恶性病变患者PI值 < 1.0和RI值 < 0.4比例差异均有统计学意义（χ² = 62.68，P < 0.01；χ² = 16.91，P < 0.01）。灰阶超声图像用于鉴别卵巢囊肿良恶性的敏感度、特异度、PPV和NPV分别为51.85%、75.76%、63.64%和65.79%，灰阶超声图像 + 彩色多普勒超声用于鉴别卵巢囊肿良恶性的敏感度、特异度、PPV和NPV分别为81.48%、93.94%、91.67%和86.11%，差异具有统计学意义（χ² = 16.00、12.73、15.90、12.44，P 均 < 0.01）。结论灰阶超声图像具有诊断卵巢囊肿的价值，联合应用经阴道彩色多普勒超声和灰阶超声图像可提高卵巢囊肿良恶性诊断能力。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈丽
	张小娟
	黄丽芬

关键词 ：经阴道彩色多普勒超声, 灰阶超声图像, 卵巢囊肿, 诊断价值

收稿日期: 2022-06-08

PACS:

R445.1

作者简介: 陈丽（1977—），女，江苏扬州人，本科，主治医师，主要从事妇科超声工作，E-mail：fm765@126.com

引用本文:

陈丽, 张小娟, 黄丽芬. 经阴道彩色多普勒超声用于鉴别卵巢囊肿良恶性的价值[J]. 中国辐射卫生, 2022, 31(6): 731-734.
CHEN Li, ZHANG Xiaojuan, HUANG Lifen. Clinical significance of transvaginal color Doppler ultrasound for the differential diagnosis of benign and malignant ovarian cysts. Chinese Journal of Radiological Health, 2022, 31(6): 731-734.

链接本文:

http://www.zgfsws.com/CN/10.13491/j.issn.1004-714X.2022.06.016 或 http://www.zgfsws.com/CN/Y2022/V31/I6/731

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660
[2] Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer[J]. Nat Rev Dis Primers, 2016, 2: 16061. DOI: 10.1038/nrdp.2016.61
[3] Wang B, Liu SZ, Zheng RS, et al. Time trends of ovarian cancer incidence in China[J]. Asian Pac J Cancer Prev, 2014, 15(1): 191-193. DOI: 10.7314/apjcp.2014.15.1.191
[4] He RX, Zhu B, Liu JL, et al. Women's cancers in China: a spatio-temporal epidemiology analysis[J]. BMC Womens Health, 2021, 21(1): 116. DOI: 10.1186/s12905-021-01260-1
[5] Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership[J]. Gynecol Oncol, 2012, 127(1): 75-82. DOI: 10.1016/j.ygyno.2012.06.033
[6] Stewart SL, Harewood R, Matz M, et al. Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study[J]. Cancer, 2017, 123(S24): 5138-5159. DOI: 10.1002/cncr.31027
[7] Li KM, Yin RT, Li ZY. Frailty and long-term survival of patients with ovarian cancer: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 1007834. DOI: 10.3389/fonc.2022.1007834
[8] Forstner R. Early detection of ovarian cancer[J]. Eur Radiol, 2020, 30(10): 5370-5373. DOI: 10.1007/s00330-020-06937-z
[9] Nash Z, Menon U. Ovarian cancer screening: current status and future directions[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 32-45. DOI: 10.1016/j.bpobgyn.2020.02.010
[10] Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and ovarian cancer: a comprehensive review[J]. Cancers, 2020, 12(12): 3730. DOI: 10.3390/cancers12123730
[11] Kamal R, Hamed S, Mansour S, et al. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality[J]. Br J Radiol, 2018, 91(1090): 20170571. DOI: 10.1259/bjr.20170571
[12] Kurjak PA, Shalan H, Kupesic S, et al. Transvaginal color Doppler sonography in the assessment of pelvic tumor vascularity[J]. Ultrasound Obstet Gynecol, 1993, 3(2): 137-154. DOI: 10.1046/j.1469-0705.1993.03020137.x
[13] Granato T, Porpora MG, Longo F, et al. HE4 in the differential diagnosis of ovarian masses[J]. Clin Chim Acta, 2015, 446: 147-155. DOI: 10.1016/j.cca.2015.03.047
[14] Kingsley RC, Pagali S. Imaging choice for adults with abdominal mass[J]. JAAPA, 2020, 33(11): 52-54. DOI: 10.1097/01.JAA.0000718420.41789.18
[15] Abramowicz JS, Timmerman D. Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules[J]. Am J Obstet Gynecol, 2017, 217(6): 652-660. DOI: 10.1016/j.ajog.2017.07.019
[16] Sehgal N. Efficacy of color doppler ultrasonography in differentiation of ovarian masses[J]. J Midlife Health, 2019, 10(1): 22-28. DOI: 10.4103/jmh.JMH_23_18
[17] Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses[J]. Radiographics, 2000, 20(5): 1445-1470. DOI: 10.1148/radiographics.20.5.g00se101445
[18] 赵成玉. 超声在卵巢肿瘤中的诊断价值[J]. 现代医用影像学,2010,19(3):187-189. DOI: 10.3969/j.issn.1006-7035.2010.03.026
Zhao CY. Value of ultrasound in diagnosis of ovarian tumors[J]. Modern Med Imagel, 2010, 19(3): 187-189. DOI: 10.3969/j.issn.1006-7035.2010.03.026
[19] 孙国英, 王绍文, 孙宁, 等. 超声显像对卵巢囊腺瘤的诊断及鉴别诊断价值[J]. 临床超声医学杂志,2004,6(2):83-85. DOI: 10.3969/j.issn.1008-6978.2004.02.007
Sun GY, Wang SW, Sun N, et al. The value of ultrasound in diagnosis and differentiation of ovarian cystic adenoma[J]. J Clin Ultrasound Med, 2004, 6(2): 83-85. DOI: 10.3969/j.issn.1008-6978.2004.02.007
[20] 周雪玲. 不同超声模式联合应用诊断卵巢囊性肿瘤临床研究[J]. 哈尔滨医药,2022,42(3):117-118. DOI: 10.3969/j.issn.1001-8131.2022.03.054
Zhou XL. Clinical study on combination of different ultrasound patterns for diagnosis of cystic ovarian tumors[J]. Harbin Med J, 2022, 42(3): 117-118. DOI: 10.3969/j.issn.1001-8131.2022.03.054
[21] 康利静. 经腹超声与经阴道超声诊断卵巢囊肿的临床效果分析[J]. 特别健康,2019(33):78-79. DOI: 10.3969/j.issn.2095-6851.2019.33.110
Kang LJ. Clinical effectiveness of transabdominal and transvarginal ultrasound for diagnosis of ovarian masses[J]. Spec Health, 2019(33): 78-79. DOI: 10.3969/j.issn.2095-6851.2019.33.110